Journal
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
Volume 51, Issue 6, Pages 305-320Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/10408363.2014.937522
Keywords
Atherosclerosis; metabolic syndrome; microRNAs
Categories
Funding
- National Institutes of Health [R01HL107953, R01HL106063]
- Foundation Leduqc Network of Excellence in Cardiovascular Research
Ask authors/readers for more resources
Metabolic syndrome is a complex metabolic condition caused by abnormal adipose deposition and function, dyslipidemia and hyperglycemia, which affects >47 million American adults and similar to 1 million children. Individuals with the metabolic syndrome have essentially twice the risk for developing cardiovascular disease (CVD) and Type 2 diabetes mellitus (T2D), compared to those without the syndrome. In the search for improved and novel therapeutic strategies, microRNAs (miRNA) have been shown to be interesting targets due to their regulatory role on gene networks controlling different crucial aspects of metabolism, including lipid and glucose homeostasis. More recently, the discovery of circulating miRNAs suggest that miRNAs may be involved in facilitating metabolic crosstalk between organs as well as serving as novel biomarkers of diseases, including T2D and atherosclerosis. These findings highlight the importance of miRNAs for regulating pathways that underlie metabolic diseases, and their potential as therapeutic targets for the development of novel treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available